聚焦“医保支持创新药械”，国家医保局连开五场座谈会

Core Insights - The National Healthcare Security Administration (NHSA) of China has held five symposiums focusing on "Medicare support for innovative drugs and medical devices," signaling a comprehensive approach to support the entire lifecycle of innovation in the pharmaceutical sector [1][2][4] Group 1: Comprehensive Support for Innovation - The symposiums established a support network covering the entire lifecycle of innovative drugs and devices, transitioning from "experience-based" to "data-driven" research [1] - Emphasis was placed on using real-world data to support the development and approval of innovative drugs, facilitating faster clinical application [1] - A scientific evaluation of the comprehensive value of innovative products was highlighted, providing a basis for Medicare purchasing decisions [1] Group 2: Multi-Stakeholder Engagement - The participation in the symposiums included a wide range of stakeholders, from academic institutions and research organizations to pharmaceutical companies and financial institutions, creating a collaborative environment for innovation [2] - Various entities, including hospitals and investment organizations, contributed to the discussion, enhancing the ecosystem for innovative drug and device development [2] Group 3: Integration of Key Elements - The symposiums underscored the importance of integrating data, policy, and funding to activate innovation in the pharmaceutical sector [3] - A focus on establishing a collaborative channel between Medicare data and research was emphasized, utilizing epidemiological and disease burden data to guide development [3] - Financial institutions' involvement was noted as a crucial factor in addressing the challenges of long research cycles and high investment costs [3] Group 4: Commitment to Innovation - The NHSA's leadership demonstrated a strong commitment to supporting genuine innovation, rejecting superficial or redundant innovations [4] - The consistent messaging from the NHSA indicates a determination to facilitate the global advancement of China's innovative drugs and medical devices, ultimately benefiting patients [4]